Details for Patent: 7,151,103
✉ Email this page to a colleague
Which drugs does patent 7,151,103 protect, and when does it expire?
Patent 7,151,103 protects ADDYI and is included in one NDA.
This patent has forty-two patent family members in twenty-nine countries.
Summary for Patent: 7,151,103
| Title: | Method of treating female hypoactive sexual desire disorder with flibanserin |
| Abstract: | The invention relates to the use of flibanserin, or a pharmaceutically acceptable acid addition salt thereof, for the treatment of disorders of sexual desire. |
| Inventor(s): | Borsini; Franco (Bad Waldsee, DE), Evans; Kenneth Robert (Toronto, CA) |
| Assignee: | Boehringer Ingelheim Pharma KG (Ingelheim, DE) |
| Application Number: | 10/272,603 |
|
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 7,151,103
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sprout Pharms | ADDYI | flibanserin | TABLET;ORAL | 022526-001 | Aug 18, 2015 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | USE OF FLIBANSERIN OR A PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF TO TREAT HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 7,151,103
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| 01125020 | Oct 20, 2001 | |
